# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-058318
Filing Date
2024-05-08
Accepted
2024-05-07 21:52:05
Documents
5
Period of Report
2024-06-21

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm242764-1_def14a.htm | DEF 14A | 747055
2 | GRAPHIC | bc_paidvsnetloss-4c.jpg | GRAPHIC | 63859
3 | GRAPHIC | bc_paidvstsr-4c.jpg | GRAPHIC | 51873
4 | GRAPHIC | px_24cyclacelpxy1pg01-bw.jpg | GRAPHIC | 244178
5 | GRAPHIC | px_24cyclacelpxy1pg02-bw.jpg | GRAPHIC | 223906
| Complete submission text file | 0001104659-24-058318.txt |  | 1487693

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 24924023
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)